MATTHEW CULBRETH: Open Payments
NPI 1790352722 · JEFFERSONVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,082 in 91 payments from 14 companies in 2025. Trend: 2023 $1,370 · 2024 $1,522 · 2025 $2,082
Food & beverage: $1,891Education: $191
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 22 | $582 |
| Alkermes, Inc. | 16 | $505 |
| Otsuka America Pharmaceutical, Inc. | 16 | $258 |
| ABBVIE INC. | 11 | $167 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $159 |
| E.R. Squibb & Sons, L.L.C. | 3 | $82 |
| Janssen Pharmaceuticals, Inc | 2 | $60 |
| Indivior Inc. | 2 | $48 |
| Neurocrine BioSciences, Inc. | 2 | $47 |
| Vanda Pharmaceuticals Inc. | 2 | $46 |
Products named: ARISTADA, UZEDY, VRAYLAR, CAPLYTA, REXULTI, LYBALVI, ABILIFY ASIMTUFII, COBENFY.
Industry payments across IN — which companies pay providers there.
